This document is a publication of a United States Patent Application (US20260083858A1) filed by Robin Carr, Roberto Solari, Edward William Tate, Andrew Simon Bell, and Roger Bonnert. The application pertains to antibody drug conjugates (ADCs) that incorporate an NMT inhibitor linked to an antibody, and their potential uses, particularly in the context of cancer treatment as indicated by the CPC classification A61P 35/00.

As this is a patent application publication, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property developments in the field of oncology drug development. Companies involved in ADC research and development, particularly those working with NMT inhibitors, should be aware of this filing as it may impact their own patent strategies and competitive landscape.